About us
Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
Information
- 2024-10 EB Announces Exclusive Licensing Agreement with PBI Portugal Unipessoal Lda., a wholly owned subsidiary of the German group Pharma Bavaria International
- 2024-10 EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's Disease.
- 2024-10 EB's proprietary 'METHOD FOR TREATING EPIDERMO-LYSIS BULLOSA' has been granted patent approval by the Intellectual Property Office
- 2024-09 Energenesis's Novel Diabetic Foot Ulcer Gel Wins Excellence Award in Innovation Technology at 2024 Taipei Biotech Awards
- 2024-09 Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry